This randomized trial evaluated the effect of zoledronic acid on femoral bone mineral density (BMD) following primary total hip arthroplasty. Bone mineral density was compared for up to 2 years in 27 patients receiving 5 mg zoledronic acid intravenous infusion and in 24 patients receiving placebo at 2 weeks and 1 year after surgery. Zoledronic acid prevented loss of bone mineral density at 1 year (+13.8% vs +1.4%, P=.0065) and 2 years (+14.3% vs −4.0%, P<.0001) in Gruen zone 1, at 1 year (−8.4% vs −25.4%, P<.0001) and 2 years (−9.6% vs −27.3%, P<.0001) in Gruen zone 7, at 6 weeks, 6 months, and 1 or 2 years in Gruen zones 4 and 6. For all Gruen zones, prevention of BMD loss by ZOL was significant at 6 weeks, 6 months, 1 year (+0.80% vs −6.03%, P<.0001) and 2 years (-0.16% vs −7.13%, P<.0001).
CoxaPro
> Clinical Library > Welcome to the joint replacement clinical library > Effect of Zoledronic Acid on Reducing Femoral Bone Mineral Density Loss following Total Hip Arthroplasty
The Journal of Arthroplasty, Volume 28, Issue 4, 671 - 675
Hip
Effect of Zoledronic Acid on Reducing Femoral Bone Mineral Density Loss following Total Hip Arthroplasty
Scott, David F. et al.Hip